🟢 Veracyte is trading 4.1% up today amid broader gains; direct catalyst unconfirmed

Veracyte is trading at $47.67, up 4.06%, with broader market strength the likeliest context; a direct catalyst remains unconfirmed.

• No verified company-specific announcement clearly explains the October 5 move. Veracyte reported Decipher prostate-test findings from a phase III trial analysis presented at ASTRO, but reporting does not establish them as the cause.
• The supplied context shows the S&P 500 up 0.58% and Nasdaq Composite up 0.99%; Reuters also reported both indexes higher during October 5 trading.